The biosimilar's safety and immunogenicity profiles were found to be comparable to those of the reference product in the trial.

The trial demonstrated pharmacokinetic equivalence to the US-licensed and EU-authorized reference product, ORENCIA®. KSHB002, a 125 mg/mL pre-filled syringe injection, was evaluated in a ...

Abatacept, a CTLA4–Fc fusion protein that modulates T-cell activation, has been developed for the treatment of rheumatoid arthritis. Tay et al. evaluated the effect of abatacept on vaccination ...

Our objective was to assess the efficacy of infliximab, adalimumab and abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate. The purpose of this type of ...